SuperScanner's

[geraldr]

CURX--Mr. Wright commented, saying, "Aside from dealing with transitional items, the new leadership team has been working diligently since June on advancing the Company's therapeutic platform in clinical trials and firming up our intellectual property position. We believe that a partner company with neuroscience depth could leverage and capitalize on our existing and completed preclinical and clinical work in Alzheimer's. Our efforts are focused on finding a strong development partner. Alzheimer's disease continues to be one of the world's largest unmet medical needs and we are optimistic that our therapeutic platform could modify the progression of the disease in diagnosed patients and also complement current symptomatic treatments available."